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Summary
Background Little information is available about the geo-economic variations in demographics, management, and 
outcomes of patients with acute respiratory distress syndrome (ARDS). We aimed to characterise the effect of these 
geo-economic variations in patients enrolled in the Large Observational Study to Understand the Global Impact of 
Severe Acute Respiratory Failure (LUNG SAFE).
Methods LUNG SAFE was done during 4 consecutive weeks in winter, 2014, in a convenience sample of 459 intensive-
care units in 50 countries across six continents. Inclusion criteria were admission to a participating intensive-care 
unit (including transfers) within the enrolment window and receipt of invasive or non-invasive ventilation. One of the 
trial’s secondary aims was to characterise variations in the demographics, management, and outcome of patients with 
ARDS. We used the 2016 World Bank countries classification to define three major geo-economic groupings, namely 
European high-income countries (Europe-High), high-income countries in the rest of the world (rWORLD-High), 
and middle-income countries (Middle). We compared patient outcomes across these three groupings. LUNG SAFE is 
registered with ClinicalTrials.gov, number NCT02010073.
Findings Of the 2813 patients enrolled in LUNG SAFE who fulfilled ARDS criteria on day 1 or 2, 1521 (54%) were 
recruited from Europe-High, 746 (27%) from rWORLD-High, and 546 (19%) from Middle countries. We noted 
significant geographical variations in demographics, risk factors for ARDS, and comorbid diseases. The proportion of 
patients with severe ARDS or with ratios of the partial pressure of arterial oxygen (PaO2) to the fractional concentration 
of oxygen in inspired air (FIO2) less than 150 was significantly lower in rWORLD-High countries than in the two other 
regions. Use of prone positioning and neuromuscular blockade was significantly more common in Europe-High 
countries than in the other two regions. Adjusted duration of invasive mechanical ventilation and length of stay in the 
intensive-care unit were significantly shorter in patients in rWORLD-High countries than in Europe-High or Middle 
countries. High gross national income per person was associated with increased survival in ARDS; hospital survival 
was significantly lower in Middle countries than in Europe-High or rWORLD-High countries.
Interpretation Important geo-economic differences exist in the severity, clinician recognition, and management of 
ARDS, and in patients’ outcomes. Income per person and outcomes in ARDS are independently associated.
Funding European Society of Intensive Care Medicine, St Michael’s Hospital, University of Milan-Bicocca.
Introduction
Important geographical and economic variations in 
epidemiology and patterns of care have been described 
for diseases including diabetes,1 asthma,2 myocardial 
infarction,3,4 heart failure,5 atrial fibrillation,6 chronic 
obstructive pulmonary disease (COPD),7 end-stage 
kidney disease,8 and breast cancer.9 Furthermore, use of 
interventions such as blood transfusion,10 amputation,11 
aneurysm repair,12 and carotid revascularisation13—and 
outcomes after interventions such as coronary artery 
bypass grafting14—also vary by region or socioeconomic 
status, or both. Thus, geo-economic variations in the 
epidemiology and manage ment of patients with acute 
respiratory distress syndrome (ARDS) could have 
important effects on patient outcomes, but the extent 
and implications of these variations have not been 
characterised.
The Large Observational Study to Understand the 
Global Impact of Severe Acute Respiratory Failure 
(LUNG SAFE)15 in 459 intensive-care units (ICUs) in 
50 countries on six continents showed a two-fold 
variation in the incidence of ARDS per ICU bed across 
the continents, which was independent of clinician 
recognition. ARDS was under-recognised by clinicians, 
and the use of evidence-based ventilatory strategies and 
adjuncts was less common than expected. Of most 
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concern, ARDS had high mortality, with 40% of patients 
dying in hospital.15
A key secondary aim of LUNG SAFE was to characterise 
geo-economic variations in demographics, management, 
and outcomes of patients with ARDS. We compared 
patients across three major geo-economic groupings.
Methods
Study design and participants
Detailed methods for LUNG SAFE have been published 
elsewhere.15 Briefly, LUNG SAFE was an international, 
multicentre, prospective cohort study, with a 4-week 
enrolment window during the winter in each hemi-
sphere.15 The study, which was conceived by the Acute 
Respiratory Failure Section of the European Society of 
Intensive Care Medicine, was endorsed by several 
national societies and networks (appendix). Its primary 
outcomes were to determine the incidence of ARDS in 
ICUs, and management of ARDS and patient outcomes 
in the era of the Berlin definition. All participating ICUs 
obtained ethics committee approval. Patients either 
provided informed consent, or the need for consent was 
waived by ethics committees. National coordinators and 
site investigators were responsible for obtaining ethics 
approval and ensuring the integrity and validity of data.
Inclusion criteria were admission to a participating 
ICU (including ICU transfers) within the enrolment 
window and receipt of invasive or non-invasive 
ventilation. An extended dataset was composed of all 
patients receiving continuous positive airway pressure 
therapy of 5 cm H2O, or assisted ventilation (invasive or 
non-invasive) with positive end-expiratory pressure 
continuous positive airway pressure therapy of 5 cm or 
more H2O and a ratio of the partial pressure of arterial 
oxygen (PaO2) to the fractional concentration of oxygen 
in inspired air (FIO2)  of less than 300. Exclusion criteria 
were age younger than 16 years or inability to obtain 
informed consent (when required). Patients were 
classified as having ARDS on the basis of the Berlin 
criteria.16 To ensure a homogenous dataset, we restricted 
subsequent analyses in this Article to the large subset 
(2813 [93%] of 3022 patients) fulfilling the criteria for 
ARDS on day 1 or day 2 after the onset of acute 
hypoxaemic respiratory failure. Data from the first day of 
fulfilment of ARDS criteria were used in these analyses.
Data definitions
We used the 2016 World Bank countries classification, 
which includes data for gross national income per 
person, to define three major geo-economic groupings: 
high-income countries in Europe (Europe-High), high-
income countries in the rest of the world (rWORLD-
High), and middle-income countries (Middle).
Duration of invasive ventilation was calculated as the 
number of days that the patient required invasive 
mechanical ventilation up to day 28. Driving pressure was 
defined as plateau pressure minus positive-end expira tory 
pressure. Plateau and driving-pressure analyses were 
confined to patients (n=742) in whom plateau pressure 
was measured and in whom no evidence of spontaneous 
ventilation was detected (ie, when set and measured 
respiratory rates were equal). All modes other than 
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Research in context
Evidence before this study
We searched PubMed with the terms “respiratory distress 
syndrome, adult” [MeSH terms] OR (“respiratory” [all fields] 
AND “distress” [all fields] AND “syndrome” [all fields] AND 
“adult” [all fields]) OR “adult respiratory distress syndrome” [all 
fields] OR (“acute” [all fields] AND “respiratory” [all fields] AND 
“distress” [all fields] AND “syndrome” [all fields]) OR “acute 
respiratory distress syndrome” [all fields]) AND “geographic” 
[all fields] OR “country” [all fields] for articles published in any 
language between Jan 1, 1990, and Dec 31, 2016, the date of 
our final search. We also reviewed the reference lists of 
publications identified by our search strategy. We found some 
studies of the epidemiology of acute respiratory distress 
syndrome (ARDS) within regions or small groups of countries 
(eg, Europe), but no data for ARDS across major geo-economic 
groupings. We also identified studies showing important geo-
economic variations in diseases such as diabetes, asthma, 
chronic obstructive pulmonary disease, and myocardial 
infarction.
Added value of this study
Significant variations exist in demographics, risk factors for 
ARDS, and comorbid diseases across the three major 
geo-economic groupings included in our study—namely, 
high-income countries in Europe, high-income countries in the 
rest of the world, and middle-income countries. Severity of 
ARDS was less overall in high-income countries in the rest of 
the world than in high-income European or middle-income 
countries. In terms of patterns of care, use of prone positioning, 
neuromuscular blockade, and recruitment manoeuvres were 
more common in high-income European countries than in the 
other two geo-economic groups. Length of stay in 
intensive-care units was shorter, and unassisted ventilation 
to day 28 was more common, in high-income countries in the 
rest of the world than in high-income European or 
middle-income countries. Lower gross national product was 
associated with poorer hospital survival in patients with ARDS. 
Outcomes in middle-income countries were worse than those 
in either high-income country grouping.
Implications of all the available evidence
Important regional differences exist in the demographics, 
management, and outcomes of patients with ARDS. Our data 
show opportunities to increase implementation of 
evidence-based interventions that improve outcomes for 
patients.
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volume and pressure control modes were judged to 
permit spontaneous breathing. Mortality was assessed on 
day 28, at discharge from ICU, and at discharge from 
hospital (or on day 90, whichever came first).
Statistical analysis
Descriptive statistics included proportions for categorical 
variables and mean (SD) for continuous variables. No 
assumptions were made for missing data, which were 
rare.15 Data were unadjusted unless specifically stated 
otherwise. We used the χ² test and ANOVA or Kruskal-
Wallis test (as appropriate) to assess differences among 
geo-economic groupings. We used the Shapiro-Wilk test 
to assess normality in data distribution. Bonferroni 
correction was applied to determine significance in the 
setting of multiple comparisons. We did Kaplan-Meier 
analysis to estimate the likelihood of liberation from 
invasive mechanical ventilation and of hospital mortality 
within 28 days of onset of acute hypoxaemic respiratory 
failure. We assumed that patients discharged alive from 
hospital before 28 days were alive on day 28. In the 
survival analysis, we used the log-rank test to compare 
survival curves among geo-economic groups.
We used mixed-effect logistic regression to assess the 
association between mortality and ICU-level predictors. 
We used a two-level random intercept model for binary 
responses: the first level was represented by individuals 
and the second level by ICUs. Demographic, risk, illness 
severity, and management factors were included in the 
first level; gross national income per person, geographical 
area, and ICU characteristics (number of beds, academic 
or non-academic ICU, beds per nurse, beds per doctor, 
and proportion of the total number of beds in a hospital 
that ICU beds account for) were included on the second 
level. Because some ICUs had too few observations to 
support the normal assumptions of the model, we 
applied the bootstrap method (1000 samples randomly 
extracted) to estimate the model parameters, odds ratio 
(ORs), and CIs. The individual predictors (ie, level one) 
were identified through the stepwise approach (forward 
and backward selection combined with a significance 
level of 0·05 both for entry and retention) and applied to 
a logistic re gression. We included these predictors in a 
mixed-effect logistic regression model and then, one by 
one, we assessed the significance of each ICU variable 
(ie, level two). Analogously, we applied the mixed-effect 
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8407 did not develop acute hypoxic respiratory failure
1477 did not develop acute respiratory distress syndrome
1455 had acute hypoxic respiratory failure of other causes*
582 pneumonia
392 heart failure
169 chronic obstructive pulmonary disease
17 asthma
217 other
156 unknown 
22 had unclassified disease
209 did not develop acute respiratory distress syndrome 
on days 1 or 2
2813 with acute respiratory distress syndrome on day 1 or 2
4499 had acute hypoxic respiratory failure
12 906 patients from 459 intensive-care units in 435 hospitals
included in the analysis
3022 had acute respiratory distress syndrome included in the
primary analysis
546 (19%) in middle-income countries
153 (28%) with mild disease
259 (47%) with moderate disease
134 (25%) with severe disease
746 (27%) in high-income countries in the rest of 
the world
267 (36%) with mild disease
342 (46%) with moderate disease
137 (18%) with severe disease
1521 (54%) in European high-income countries
413 (27%) with mild disease
737 (49%) with moderate disease
371 (24%) with severe disease
Figure 1: Flowchart of study population
*Patients could have more than one cause for acute hypoxic respiratory failure.
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See Online for appendix
For the 2016 World Bank 
countries classification see 
http://databank.worldbank.org/
data/home.aspx
Participating 
ICUs
Academic 
ICUs
Enrolled 
patients
Patients with 
acute respiratory 
distress syndrome 
on day 1 or 2
ICU beds Percentage of ICU 
beds in hospital
Nurse-to-bed 
ratio (daytime)
Physician-to-bed 
ratio (daytime)
High-income 
European countries
229 145 (63%) 6717 1521 (23%) 12 (9–17) 2·1% (1·4–3·2) 0·6 (0·4–0·9) 0·3 (0·2–0·4)
Austria 1 1 (100%) 18 3 (17%) 8 (8–8) 0·4% (0·4–0·4) 0·9 (0·9–0·9) 0·5 (0·5–0·5)
Belgium 6 5 (84%) 145 36 (25%) 15 (14–22) 1·8% (1·3–5·4) 0·5 (0·5–0·5) 0·1 (0·1–0·1)
Czech Republic 1 1 (100%) 24 2 (8%) 23 (23–23) 1·8% (1·8–1·8) 0·2 (0·2–0·2) 0·1 (0·1–0·1)
Denmark 2 2 (100%) 70 22 (31%) 19 (14–23) 2·5% (1·9–3·1) 1·0 (1·0–1·1) 0·3 (0·2–0·3)
France 41 21 (51%) 1312 347 (26%) 15 (12–17) 1·7% (1·3–2·5) 0·4 (0·4–0·5) 0·3 (0·2–0·4)
Germany 6 2 (33%) 275 17/275 (6%) 11 (10–14) 3·2% (2·2–3·8) 0·4 (0·3–0·4) 0·3 (0·2–0·4)
Greece 5 3 (60%) 100 18 (18%) 7 (7–9) 1·3% (1·0–1·6) 0·7 (0·7–0·8) 0·7 (0·6–0·7)
Ireland 8 8 (100%) 277 101 (36%) 13 (8–17) 2·1% (1·4–2·6) 1·2 (1·2–1·3) 0·1 (0·1–0·1)
Italy 32 16 (50%) 752 125 (17%) 8 (8–10) 1·4% (1·1–2·0) 0·5 (0·5–0·6) 0·3 (0·2–0·4)
Latvia 1 1 (100%) 19 5 (26%) 19 (19–19) 4·8% (4·8–4·8) 0·4 (0·4–0·4) 0·2 (0·2–0·2)
Netherlands 7 3 (43) 412 59 (14%) 27 (15–32) 3·7% (2·7–4·2) 0·8 (0·7–0·9) 0·1 (0·1–0·1)
Norway 4 3 (75%) 116 33 (28%) 11 (10–21) 2·8% (1·3–4·5) 1·0 (0·9–1·1) 0·3 (0·2–0·3)
Poland 1 1 (100%) 13 5 (38%) 8 (8–8) 0·7% (0·7–0·7) 1·0 (1·0–1·0) 0·3 (0·3–0·3)
Portugal 11 5 (46%) 247 80 (32%) 8 (6–14) 1·9% (1·7–2·2) 0·7 (0·6–0·8) 0·5 (0·5–0·6)
Spain 45 39 (87%) 1030 259 (25%) 17 (12–20) 3·0% (2·7–4·3) 0·5 (0·4–0·5) 0·4 (0·4–0·6)
Sweden 10 8 (80%) 330 65 (20%) 9 (7–10) 1·4% (1·2–1·9) 0·7 (0·7–0·8) 0·4 (0·3–0·5)
Switzerland 2 1 (50%) 136 22 (16%) 21 (6–35) 3·2% (2·4–4·0) 0·8 (0·7–0·9) 0·3 (0·2–0·3)
UK 46 25 (54%) 1441 322 (22%) 12 (9–19) 2·2% (1·6–3·2) 1·0 (0·8–1·1) 0·1 (0·1–0·2)
High-income 
countries 
(rest of world)
110 79 (72%) 3615 746 (21%) 16 (10–22) 3·1% (2·0–6·1) 0·8 (0·5–1·0) 0·1 (0·1–0·3)
Australia 12 12 (100%) 695 125 (18%) 17 (13–24) 3·3% (2·7–4·9) 1·2 (1·0–1·3) 0·1 (0·1–0·2)
Brunei 1 1 (100%) 21 5 (24%) 26 (26–26) 4·7% (4·7–4·7) 0·5 (0·5–0·5) 0·1 (0·1–0·1)
Canada 8 8 (88%) 380 88 (23%) 24 (18–26) 5·8% (4·3–9·6) 1·0 (0·9–1·1) 0·1 (0·1–0·1)
Chile 7 4 (57%) 116 37 (32%) 9 (8–16) 2·6% (2·3–7·5) 0·3 (0·3–0·4) 0·1 (0·1–0·4)
Japan 28 15 (54%) 643 81 (13%) 10 (8–15) 2·0% (1·2–3·0) 1·0 (0·8–1·2) 0·3 (0·2–0·3)
New Zealand 6 3 (50%) 142 27 (19%) 9 (6–16) 2·2% (2·0–2·8) 0·9 (0·8–1·1) 0·2 (0·2–0·2)
Saudi Arabia 7 5 (71%) 120 57 (48%) 9 (8–20) 1·7% (0·8–3·4) 1·1 (1·0–2·8) 0·2 (0·1–0·5)
USA 35 31 (89%) 1421 306 (22%) 20 (12–25) 4·1% (2·0–6·4) 0·7 (0·5–0·8) 0·1 (0·1–0·1)
Uruguay 6 1 (17%) 77 20 (26%) 10 (10–14) 8·3% (5·6–14·0) 0·3 (0·3–0·6) 0·3 (0·3–0·4)
Middle-income 
countries
120 76 (63%) 2574 546 (21%) 15 (10–23) 2·7% (1·5–6·7) 0·6 (0·5–0·9) 0·3 (0·1–0·4)
Albania 2 2 (100%) 32 3 (9%) 15 (15–15) 1·1% (1·1–1·1) 0·3 (0·3–0·3) 0·3 (0·3–0·3)
Argentina 18 12 (67%) 280 77 (28%) 12 (8–16) 6·0% (3·8–10·0) 0·5 (0·5–0·6) 0·4 (0·3–0·4)
Brazil 8 2 (25%) 47 18 (38%) 10 (8–10) 10·8% (5·0–11·3) 0·2 (0·1–0·3) 0·2 (0·1–0·2)
China 35 21 (60%) 1181 189 (16%) 20 (16–30) 1·5% (0·9–1·8) 0·8 (0·6–1·2) 0·3 (0·2–0·5)
Colombia 1 1 (100%) 89 39 (44%) 80 (80–80) ·· ·· 0·1 (0·1–0·1)
Costa Rica 2 2 (100%) 30 13 (43%) 12 (8–16) 1·8% (1·0–2·6) 0·5 (0·5–0·5) 0·1 (0·1–0·1)
Ecuador 2 1 (50%) 2 1 (50%) 12 (12–12) 4·8% (4·8–4·8) 0·3 (0·3–0·3) 0·3 (0·3–0·3)
Guatemala 2 2 (100%) 25 2 (8%) 10 (10–10) 16·7% (16·7–16·7) 0·6 (0·4–0·8) 0·4 (0·1–0·6)
India 10 4 (40%) 206 56 (27%) 19 (14–29) 4·7% (2·4–10·8) 0·8 (0·6–1·0) 0·1 (0·1–0·2)
Iran 2 1 (50%) 61 9 (15%) 28 (26–30) 5·8% (3·0–8·7) 1·2 (0·6–1·9) 0·1 (0·1–0·2)
Lebanon 1 0 (0%) 1 1 (100%) ·· ·· ·· ··
Malaysia 1 0 (0%) 6 0 (0%) 3 (3–3) 1·5% (1·5–1·5) 0·7 (0·7–0·7) 0·3 (0·3–0·3)
Mexico 10 8 (80%) 118 40 (34%) 9 (6–11) 4·4% (2·7–6·9) 0·8 (0·7–1·0) 0·3 (0·3–0·5)
Morocco 5 4 (80%) 48 12 (25%) 10 (7–21) 1·7% (1·1–2·3) 0·8 (0·6–1·5) 0·4 (0·2–0·6)
Peru 2 1 (50%) 51 5 (9%) 20 (15–24) 4·4% (1·6–7·1) 0·5 (0·4–0·5) 0·2 (0·1–0·3)
Philippines 2 1 (50%) 18 5 (28%) 16 (12–20) 2·8% (1·7–3·9) 0·9 (0·7–1·0) 0·1 (0·0–0·1)
(Table 1 continues on next page)
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Poisson regression to assess the association between 
ICU-level predictors and length of stay in the ICU and 
duration of invasive mechanical ventilation.
Statistical analyses were done with R (version 3.0.2) 
and SAS (version 9.4). All p values were two-sided, and 
values less than 0·05 were deemed significant. The study 
protocol, case-report form, and full statistical analysis 
plan are in the appendix.
Role of the funding source
The study funders had no role in study design; data 
collection, analysis, or interpretation; or writing of the 
Article. JGL, FM, GB, TP, and EF had access to the raw 
data. The corresponding author had full access to all data 
and final responsibility for the decision to submit for 
publication.
Results
Of the 12 906 patients screened for the LUNG SAFE 
study, 2813 (22%) fulfilled ARDS criteria on day 1 or 2 
after enrolment. Of these 2813 participants, 1521 (54%) 
were recruited from Europe-High, 746 (27%) from 
rWORLD-High, and 546 (19%) from Middle countries 
(figure 1). In Europe-High countries, 23% of screened 
patients had ARDS, compared with 21% in both 
rWORLD-High and Middle countries (table 1). Overall 
300 (65%) of the 459 participating ICUs were in academic 
hospitals, with a median of 14 beds (IQR 9–20) per ICU, 
a median nurse-to-bed daytime ratio of 0·6 (0·5–1·0), 
and a median physician-to-bed daytime ratio of 0·3 
(0·1–0·4).
Patients from Europe-High countries were significantly 
older (p<0·01 vs r-WORLD-High; p<0·0001 vs Middle; 
table 2). Body-mass index was signicantly higher in 
patients in rWORLD-High countries than in those in 
Europe-High countries (p=0·0076), who in turn had 
significantly higher body-mass indices than those in 
Middle countries (p<0·0001; table  2). Diabetes mellitus, 
chronic renal failure, and liver disease were significantly 
more frequent pre-existing comorbidities in rWORLD-
High countries than in Europe-High or Middle countries, 
whereas congestive heart failure was more common in 
patients from Middle countries than in those from 
rWorld-High countries (appendix). Pneumonia was the 
dominant risk factor for ARDS across each group 
(appendix). Extra-pulmonary sepsis was significantly 
more common in Middle countries than in Europe-High 
or rWORLD-High countries, and differences were also 
noted in the frequency of trauma, inhalational injury, 
pancreatitis, and the presence of no risk factors in 
patients with ARDS (appendix).
Severity of ARDS varied by region, with mild disease 
signifi cantly more common, and severe disease signifi-
cantly less common in rWORLD-High countries than in 
Europe-High or Middle countries (table 2; appendix). 
The proportions of patients with a PaO2:FIO2 ratio of less 
than 150 and patients with persistent severe ARDS were 
significantly lower in rWORLD-High countries than in 
Europe-High countries (table 2). Mean PaO2:FIO2 ratios 
were significantly higher in rWORLD-High countries 
than in Europe-High and Middle countries (p<0·0001 
for both comparisons; table 2). Worst non-pulmonary 
sepsis-related organ failure assessment (SOFA) scores 
were significantly lower in Europe-High countries than 
in rWorld-High (p=0·0163) or Middle (p=0·0004) 
countries (table 2).
Clinician recognition of ARDS was significantly less 
common in rWORLD-High than in Europe-High or 
Middle countries (p<0·0001 for both comparisons; 
table 3). Significantly more patients (67%) received 
lower tidal volumes (≤8 mL/kg of predicted bodyweight) 
in rWORLD-High countries than in Europe-High (62%; 
p=0·02) and Middle countries (61%; p=0·02; figure 2A). 
The proportion of patients in whom plateau pressure 
was measured was highest in patients from Middle 
countries (table 3). The distributions of driving 
pressures were similar acrosss the three regions 
(figure 2C). Over 50% of patients in Middle countries 
had a positive end expiratory pressure of less than 
7·5 cm H2O, compared with 44% of participants in 
Europe-High (p=0·0011) and 40% in rWORLD-High 
countries (p<0·0001; figure 2D). 
Participating 
ICUs
Academic 
ICUs
Enrolled 
patients
Patients with 
acute respiratory 
distress 
syndrome on day 
1 or 2
ICU beds Percentage of ICU 
beds in hospital
Nurse-to-bed 
ratio (daytime)
Physician-to-bed 
ratio (daytime)
(Continued from previous page)
Romania 3 3 (100%) 106 19 (18%) 28 (18–38) 3·1% (2·3–3·5) 0·3 (0·2–0·5) 0·1 (0·1–0·2)
Russia 2 2 (100%) 11 3 (27%) 78 (78–78) 7·1% (7·1–7·1) 0·3 (0·3–0·3) 0·2 (0·2–0·2)
Serbia 3 2 (67%) 56 5 (9%) 25 (25–25) 2·0% (2·0–2·0) 0·5 (0·5–0·5) 0·1 (0·1–0·1)
South Africa 1 1 (100%) 70 19 (27%) 10 (10–10) 1·3% (1·3–1·3) 1·3 (1·3–1·3) 0·1 (0·1–0·1)
Tunisia 4 2 (50%) 51 15 (29%) 12 (10–13) 2·9% (1·3–4·5) 0·5 (0·5–0·5) 0·2 (0·2–0·2)
Turkey 4 4 (100%) 85 15 (18%) 19 (17–20) 1·5% (1·3–5·0) 0·4 (0·4–0·6) 0·2 (0·1–0·2)
Data are n, n (%), or median (IQR). ICU=intensive-care unit.
Table 1: Geographical distribution of participating ICUs, enrolled patients, and organisational differences
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The proportion of patients receiving protective 
ventilation (defined as a tidal volume ≤8 mL/kg of 
predicted bodyweight and plateau pressure of ≤30 cm H2O) 
did not differ significantly between geo-economic 
groupings (table 3). Spontaneous ventilation in early 
ARDS was significantly more frequent in patients from 
rWORLD-High countries than in those from Europe-High 
countries (table 3). Inspired oxygen use differed by region: 
low FiO2 (ie, FiO2 ≤0·4) was significantly more common in 
rWORLD-High countries than in Europe-High countries 
(p<0·0001), and high FiO2 (ie, >0·6) was significantly more 
frequent in Europe-High than in rWORLD-High 
(p=0·0070) or Middle (p=0·0060) countries (figure 2E). 
Hypercapnia (defined as a partial pressure of carbon 
dioxide in arterial blood [PaCO2] ≥45 mm Hg) was 
significantly more frequent in patients from Europe-High 
countries than in those from rWORLD-High countries 
(p=0·124), whereas hypocapnia was significantly more 
frequent in patients from Middle countries than in those 
from Europe-High (p<0·0001) or rWORLD countries 
(p<0·0001; appendix). Modes of ventilation differed 
by region; use of pressure support was significantly 
less common—and use of synchronised intermittent 
mandatory ventilation signifi cantly more common—in 
Middle countries than in Europe-High or rWORLD-High 
countries (appendix). Use of volume and pressure-control 
ventilation modes, and non-invasive ventilation did not 
differ by geo-economic group (figure 2; appendix).
Use of neuromuscular blockade and prone positioning 
in all patients, and in the subgroup with a PaO2:FIO2 ratio 
of less than 150, were significantly more common in 
patients from Europe-High countries than in those 
from Middle (p<0·0001 and p=0·002, respectively) or 
rWORLD-High countries (p<0·0001 for both 
comparisons; figure 2; appendix). Use of extracorporeal 
membrane oxygenation was significantly less common 
in Middle countries than in both other regions (figure 2; 
appendix). Use of recruitment manoeuvres was lower in 
rWORLD-High countries than in Middle or Europe-High 
countries (figure 2; appendix). Adjust ment for severity 
of ARDS did not account for the regional differences in 
the use of adjunctive measures (data not shown).
All 
(n=2813)
European 
high-income 
countries (n=1521)
High-income 
countries 
(rest of world) 
(n=746)
Middle-income 
countries (n=546)
p value 
(among groups)
Demographic data
Mean age (years) 61·3 (16·8) 62·6 (15·7) 60·7 (17·0)* 58·5 (18·8)* <0·0001
Male 1729 (61·5) 962 (63·2) 443 (59·4) 324 (59·3) 0·11
Men:women 1·6:1·0 1·7:1·0 1·5:1·0 1·5:1·0
Body-mass index 27·5 (8·7) 27·5 (7·3) 29·1 (12·1)* 25·5 (6·2)*† <0·0001
Acute respiratory distress syndrome severity (day 1)
Mild disease 833 (30%) 413 (27%) 267 (36%)* 153 (28%)† <0·0001
Moderate disease 1338 (48%) 737 (48%) 342 (46%) 259 (47%) 0·50
Severe disease 642 (23%) 371 (24%) 137 (18%)* 134 (25%)† 0·0032
PaO2:FIO2 <150 mm Hg 1361 (48%) 791 (52%) 309 (41%)* 261 (48%) <0·0001
Persistent severe disease‡ 197/2659 (7%) 126/1439 (9%) 26/702 (4%)* 45/518 (9%)† <0·0001
No longer fulfilling disease criteria 
after 24 h
486 (17%) 247 (16%) 143 (19%) 96 (18%) 0·22
Gas exchange (day 1)
PaO2:FIO2 at disease onset (mm Hg) 160·4 (67·3) 155·5 (65·8) 171·8 (68·7)* 158·5 (67·7)† <0·0001
SpO2 94·7 (5·2) 94·5 (5·0) 95·2 (5·0)* 94·4 (6·1) 0·0096
PaCO2 (mm Hg) 46·0 (15·4) 47·2 (14·9) 45·7 (15·6)* 43·4 (16·2)*† <0·0001
pH 7·33 (0·12) 7·32 (0·12) 7·34 (0·11)* 7·35 (0·12)* 0·0002
SOFA scores§
Day 1 9·5 (4·1) 9·3 (4·0) 9·8 (4·2) 9·8 (4·5) 0·11
Day 1 non-pulmonary score 6·3 (4·1) 6·1 (3·9) 6·7 (4·2)* 6·4 (4·4) 0·0397
Worst score 11·1 (4·4) 10·8 (4·1) 11·2 (4·5) 11·9 (4·7)*† 0·0002
Worst non-pulmonary score 8·0 (4·2) 7·7 (4·0) 8·3 (4·3)* 8·6 (4·6)* 0·0007
Data are mean (SD), n (%), or n/N (%), unless otherwise specified. Among groups p values refer to a comparison across the three geo-economic regions. p values for between-
group comparisons are in the appendix. LUNG SAFE=Large Observational Study to Understand the Global Impact of Severe Acute Respiratory Failure. PaO2=partial pressure of 
arterial oxygen. FIO2=fraction of inspired oxygen. SpO2=peripheral capillary oxygen saturation. PaCO2=partial pressure of arterial carbon dioxide. SOFA=sepsis-related organ 
failure assessment. *Significantly different from European high-income countries. †Significantly different from high-income countries in the rest of the world. ‡Defined as 
PaO2:FIO2 ≤100 mm Hg for greater than 48 h from onset of acute respiratory distress syndrome. Prevalence was calculated in patients in the intensive-care unit for at least 
48 h. §Adjusted for missing items.
Table 2: Demographic and illness severity data in patients with acute respiratory distress enrolled in LUNG SAFE
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Unadjusted duration of invasive ventilation and length 
of stay in ICUs were significantly shorter in rWORLD-
High countries than in Europe-High (p=0·0001 and 
p=0·002, respectively) or Middle countries (p=0·0002 
and p<0·0001, respectively; appen dix). Kaplan-Meier 
analyses showed significant differ ences in the probability 
of weaning from invasive ventilation at each level of 
severity of ARDS (figure 3; appendix). Probability of 
weaning was signifi cantly greater in patients from 
rWORLD-High countries than in those from Europe-
high or Middle countries (p<0·0001 for both; figure 3A). 
Multivariate analyses  showed that the adjusted incidence 
rate ratios for duration of invasive mechanical ventilation 
and length of ICU stay were significantly higher in 
Europe-High countries than in rWORLD-High countries 
(figure 4; appendix).
Unadjusted ICU and hospital mortality were both 
significantly lower in rWORLD-High countries than 
in Europe-High (p=0·0006) or Middle countries 
(p<0·0001; appendix). 28-day survival was highest in 
rWORLD-High countries and lowest in Middle 
countries (figure 3). The adjusted odds ratios for ICU 
and hospital survival were significantly higher in 
rWORLD-High and Europe-High countries than in 
Middle countries (figure 4; appendix). Differences in 
approaches to mechanical ventilation did not result in 
significant geo-economic variations in ICU or hospital 
mortality (appendix). Patient-level variables associated 
with hospital mortality included age, active or 
haematological neoplasm, chronic liver failure, acidosis, 
PaO2:FIO2, non-pulmonary SOFA score, and respiratory 
rate (table 4; appendix). We noted no independent 
association between ICU-level variables and hospital 
mortality (table 4; appendix).
In a separate multivariate analysis across all countries 
(ie, without any grouping) in which gross domestic 
product per person was a continuous variable, all-cause 
mortality in ARDS was independently associated with 
gross domestic product (table 4). Respiratory (42%) and 
cardiovascular failure (37%) were the most common 
factors leading to death in ICUs, and we noted no 
significant geographical variations (appendix). Decisions 
All European high-income 
countries
High-income 
countries 
(rest of world)
Middle-income 
countries
p value 
(among groups)
Clinical recognition of acute respiratory distress syndrome
All patients 1735/2813 (62%) 967/1521 (64%) 406/746 (54%)* 362/546 (66%)† <0·0001
Mild disease 407/833 (49%) 217/413 (53%) 113/267 (42%)* 77/153 (50%) 0·0311
Moderate disease 844/1338 (63%) 468/737 (64%) 199/342 (58%) 177/259 (68%)† 0·0360
Severe disease 484/642 (75%) 282/371 (76%) 94/137 (69%) 108/134 (81%) 0·07
Tidal volume >8 mL/kg of predicted bodyweight
All patients 937/2553 (37%) 533/1407 (38%) 210/644 (33%)* 194/502 (39%)† 0·0428
Receiving invasive mechanical 
ventilation
792/2255 (35%) 435/1210 (36%) 187/599 (31%) 170/446 (38%)† 0·0468
Airway plateau pressure measured
Invasively ventilated patients 954/2377 (40%) 487/1263 (39%) 214/649 (33%)* 253/465 (54%)*† <0·0001
Patients with controlled ventilation 762/1628 (47%) 413/954 (43%) 166/399 (42%) 183/275 (67%)*† <0·0001
Plateau pressure (cm H2O)‡ 23·20 (6·12) 23·60 (5·65) 23·30 (5·86) 22·19 (7·17)* 0·0229
Plateau pressure >30 cm H2O‡ 72/742 (10%) 34/395 (9%) 17/166 (10%) 21/181 (12%) 0·51
Positive end-expiratory pressure 
(cm H2O)
8·22 (3·21) 8·30 (3·18) 8·42 (3·48) 7·70 (2·82)*† 0·0010
Driving pressure (cm H2O) 14·73 (5·54) 15·16 (5·44) 14·36 (5·20) 14·12 (6·00) 0·08
FIO2 0·64 (0·23) 0·65 (0·23) 0·62 (0·24)* 0·63 (0·22) 0·0113
Receiving protective ventilation§ 607/957 (63%) 309/490 (63%) 143/206 (69%) 155/261 (59%) 0·08
Standardised minute ventilation 
(L/min)¶
11·3 (5·3) 11·7 (5·6) 11·0 (5·2)* 10·2 (4·6)*† <0·0001
Spontaneous ventilation in first 48 h from disease onset
All 1478/2769 (53%) 737/1492 (49%) 445/739 (60%)* 296/538 (55%) <0·0001
PaO2:FIO2 <150 mm Hg 647/1342 (48%) 343/780 (44%) 174/304 (57%)* 130/258 (50%) 0·0003
Data are n/N (%) or mean (SD). Driving pressure and plateau pressure were assessed in patients in whom no evidence of spontaneous ventilation was noted. Among groups 
p values refer to a comparison across the three geo-economic regions. p values for between-group comparisons are in the appendix. LUNG SAFE=Large Observational Study 
to Understand the Global Impact of Severe Acute Respiratory Failure. FIO2=fraction of inspired oxygen. PaO2=partial pressure of arterial oxygen. *Significantly different from 
European high-income countries. †Significantly different from high-income countries in the rest of the world. ‡Plateau pressure values were limited to patients in whom this 
value was reported and in whom either an assist control mode or a mode permitting spontaneous ventilation was used. The set and total respiratory rates were equal. 
Patients receiving high-frequency oscillatory ventilation or extracorporeal membrane oxygenation were also excluded. §Tidal volume ≤8 mL/kg and plateau pressure 
≤30 cm H2O. ¶Standardised minute ventilation=minute ventilation x partial pressure of arterial carbon dioxide/40 mm Hg.
Table 3: Management of patients with acute respiratory distress syndrome enrolled in LUNG SAFE
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about limitation of life-sustaining measures were less 
frequent in Middle (17%) than in Europe-High (27%) or 
rWORLD (26%) countries (appendix).
Discussion
In this prospective observational cohort study, we noted 
important differences in severity patterns, extent of 
clinician recognition, and approaches to manage ment 
of ARDS across geo-economic regions. Patients from 
Europe-High countries had longer durations of 
mechanical ventilation and ICU stays than did patients 
from rWORLD-High countries. We show for the first time 
(to our knowledge) that indices of national socioeconomic 
status are associated with survival in ARDS.
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Figure 2: Tidal volume (A), plateau pressure (B), driving pressure (C), positive end-expiratory pressure (D), FIO2 (E), and adjunctive measures (F), by geo-economic 
region
Error bars represent 95% CIs. p values for between-group comparisons are in the appendix. FIO2=fractional concentration of oxygen in inspired air. 
Europe-High=high-income European countries. rWORLD-High=high-income countries in the rest of the world. Middle=middle-income countries. NIV=non-invasive 
ventilation. NMB=neuromuscular blockade. ECMO=extracorporeal membrane oxygenation. Recruit=recruitment manoeuvres. P-esoph=oesophageal pressure. 
*Shows significant between-region differences.
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Although the patients from the three regions differed 
significantly in terms of their demographics, the effect of 
these differences on outcomes seems small. The older 
age of patients from Europe-High countries could partly 
explain the higher unadjusted mortality in this region 
compared with rWORLD-High and Middle countries, 
because age was independently associated with hospital 
mortality in this and previous studies.17–19 Of the pre-
existing comorbidities associated with poor outcomes, 
only chronic liver failure differed significantly in 
frequency: it was more common in rWORLD-High 
countries than in Middle countries. The pattern of critical 
illnesses seemed to differ between regions: patients from 
Europe-High countries had greater severity of ARDS and 
were more likely to have persistent severe disease than 
those from rWORLD-High countries, whereas those 
from rWORLD-High countries had more severe systemic 
illness than those from Europe-High countries. As has 
previously been shown, both severity of ARDS and non-
pulmonary SOFA scores were independently associated 
with hospital mortality.19
The greater use in Europe-High countries of neuro-
muscular blockade and prone positioning in patients 
with a PaO2:FIO2 ratio of less than 150 could reflect the 
fact that these approaches were largely developed in 
Europe-High countries,20,21 and might have penetrated to 
a lesser extent to the rest of the world. Other possible 
explanations include the unavailability of cisatracurium 
in some countries or lack of hands-on experience with 
prone positioning. Even in Europe-High countries, 
however, prone positioning was used in less than 10% of 
patients with a PaO2:FIO2 ratio of less than 150, the 
population in which proning improves outcomes.20 A 
large clinical trial is being done in the USA by the PETAL 
network (NCT02509078) to address uncertainty about 
the efficacy of neuromuscular blockade in ARDS. 
Variations in the use of adjunctive measures cannot be 
explained by differences in severity profile, economic 
differences (with the possible exception of extracorporeal 
membrane oxygenation, which was used less often in 
Middle countries), or by differences in recognition of 
ARDS. The absence of regional variation in the use of 
non-invasive ventilation suggests that barriers to the use 
of adjuncts can be addressed.22 Understanding and 
addressing local barriers to, and facilitators of, 
implementation of simple and inexpensive adjunctive 
measures, such as prone positioning and neuromuscular 
blockade, should be prioritised, in view of the potential 
to improve survival.
Patients from Europe-High countries had longer 
durations of mechanical ventilation and ICU stays than 
did those from rWORLD-High countries. These differ-
ences persisted after adjustment for disease severity and 
other covariates. Importantly, we found no associations 
between ICU-level variables and outcomes from ARDS, 
suggesting that differences in ICU organisation or staffing 
do not explain the effect of income. This finding implies 
that differences in approaches to manage ment of ARDS 
could have important impli cations for these highly 
patient-centred outcomes. Potential explanations include 
that the proportion of patients who received large tidal 
volumes was lowest in rWORLD-High countries and 
highest in Europe-High countries, a concern because high 
tidal volumes have been associated with poor outcomes.23 
The greater use of higher oxygen concentrations (ie, FIO2 
>0·6) in patients from Europe-High countries is of 
concern, because use of high FiO2 in critically ill patients 
could be harmful.24 Other potential explanations include 
differences in practices for weaning from ventilation, but 
we do not have any data to examine this issue.
Clinician recognition of ARDS was significantly lower 
in rWORLD-High countries than in Europe-High 
countries, although the difference was not significant for 
Figure 3: Kaplan-Meier curves of probability of weaning from mechanical ventilation (A) and hospital 
survival (B), by geo-economic region
Patients discharged before day 28 were assumed to be alive and off invasive mechanical ventiation on that day. 
HRs were estimated with Cox proportional hazard models; we used rWORLD-High as the reference category. 
We used the log-rank test to assess the differences between curves. HR=hazard ratio. Europe-High=high-income 
European countries. rWORLD-High=high-income countries in the rest of the world. Middle=middle-income 
countries.
A
Number at risk
Europe-High
rWORLD-High
Middle
0
Europe-High HR 1·18 (95% CI 1·01–1·38)
Middle HR 1·29 (95% CI 1·07–1·56)
p<0·0001
Europe-High HR 0·70 (95% CI 0·62–0·79)
Middle HR 0·66 (95% CI 0·56–0·77)
p=0·0188
5 10 15 20 25
1332
650
481
1112
480
405
898
352
325
759
278
272
686
248
253
635
232
238
0
0·2
0·4
0·6
0·8
1·0
Pr
ob
ab
ili
ty
 o
f w
ea
ni
ng
B
Number at risk
Europe-High
rWORLD-High
Middle
0 5 10 15 20 25
1519
743
541
1271
649
464
1160
584
415
1083
555
385
1036
526
358
995
516
336
Time to event (days)
0
0·2
0·4
0·6
0·8
1·0
Pr
ob
ab
ili
ty
 o
f s
ur
vi
va
l
Europe-High
rWORLD-High
Middle
Articles
10 www.thelancet.com/respiratory   Published online June 14, 2017   http://dx.doi.org/10.1016/S2213-2600(17)30213-8
severe disease. Decision making about limitation of life-
sustaining measures was similar in Europe-High and 
rWORLD-High countries, so it is unlikely to explain these 
differences in duration of mechanical ventilation and 
ICU stays. Better understanding of the reasons underlying 
differences in recognition of ARDS, the use of lower tidal 
volume ventilation, inspired oxygen concentrations, and 
adjuncts to ventilation could help to further improve 
these patient-relevant outcomes in ARDS.
Respiratory failure and cardiovascular failure were 
the most important factors leading to death in the ICU 
across all regions. This result contrasts to some degree 
with those of previous studies, which suggested that 
respiratory failure is less commonly the cause of death 
in ARDS.25,26 However, in previous studies, respiratory 
failure was narrowly defined as severe gas-exchange 
failure, and deaths were attributed to syndromes such 
as sepsis as well as to organ failures. We limited the list 
of possible factors to organ systems, and did not ask for 
a cause of death per se. Possible additional explanations 
for our findings include improvement in outcomes 
from the shock phases of critical illness,27 and the 
increasing role of decisions to limit life-sustaining 
measures when such measures are deemed futile.
The association of national-level indices of wealth with 
survival in ARDS is a novel and provocative finding. It 
might not reflect a different quality of care or resources 
in ICUs, but could be a result of a differing access to 
critical care services or preventive medicine.28 Data show 
that residents from low-income areas have significantly 
higher rates of ICU admission29 and more severe illness 
than do those from higher-income areas.30 Our data add 
to a growing body of evidence showing that socioeconomic 
status affects survival from illnesses. Similar relations 
between income and patient survival have been reported 
in patients with sepsis,31,32 underlining the effect of 
economic status on outcomes from critical illness. 
Studies have shown the disadvantages of low socio-
economic status on outcomes from diverse major 
medical conditions such as diabetes,7 asthma,33 acute 
myocardial infarction,34 and breast cancer.35 These data 
collectively represent a substantial public health 
challenge, and future studies are needed to elucidate the 
mechanisms by which differences in socioeconomic 
status mediate differences in outcomes, so that targeted 
interventions can be designed and assessed.
Our study has several limitations. Our cohort is a 
convenience sample, and therefore might not be 
representative of actual clinical practice in ICUs world-
wide. Thus, our results could be biased, particularly 
where specific types of ICUs (eg, academic ICUs) 
might be over-represented. Our study did not include 
any low-income countries, perhaps underlining the 
resource-dense nature of critical care. Our focus on 
winter months did not allow us to obtain annual 
incidence figures for ARDS, because previous studies 
have shown an increased incidence during winter. We 
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Figure 4: Adjusted incidence rate ratios for duration of mechanical 
ventilation and length of stay in ICU (A), and adjusted ORs of ICU and 
hospital mortality (B), by each geo-economic region
rWORLD-High is the reference point for (A) and Middle for (B). Error bars represent 
95% CIs. ICU=intensive-care unit. OR=odds ratio. Europe-High=high-income 
European countries. rWORLD-High=high-income countries in the rest of the world. 
Middle=middle-income countries.
Parameter estimate (95% CI) OR (95% CI)
Patient variables
Age (years) 0·036 (0·026 to 0·046) 1·037 (1·026 to 1·047)
Active neoplasm* 0·749 (0·198 to 1·328) 2·115 (1·219 to 3·775)
Haematological neoplasm* 1·938 (1·222 to 2·802) 6·946 (3·395 to 16·473)
Chronic liver failure* 1·569 (0·815 to 2·504) 4·801 (2·260 to 12·228)
pH –1·927 (–2·560 to –1·374) 0·146 (0·077 to 0·253)
PaO2:FIO2 (mm Hg) –0·002 (–0·005 to –0·0001) 0·998 (0·995 to 0·9999)
Non-pulmonary SOFA score (adjusted) 0·133 (0·094 to 0·174) 1·142 (1·099 to 1·190)
Respiratory rate (breaths per min) 0·047 (0·021 to 0·074) 1·048 (1·021 to 1·076)
Intensive-care unit variables
Gross domestic product† –0·017 (–0·028 to –0·007) 0·983 (0·973 to 0·993)
Number of beds –0·005 (–0·023 to 0·012) 0·995 (0·977 to 1·012)
Proportion of beds in hospital –0·001 (–0·005 to 0·005) 1·000 (0·995 to 1·005)
Beds per physician 0·009 (–0·029 to 0·053) 1·009 (0·972 to 1·054)
Beds per nurse 0·011 (–0·127 to 0·192) 1·011 (0·881 to 1·212)
Academic* –0·098 (–0·496 to 0·307) 0·907 (0·609 to 1·360)
Patients discharged before day 90 were assumed to be alive at day 90. Inclusion criteria were onset of acute respiratory 
distress syndrome within 48 h from acute hypoxaemic respiratory failure. All patient variables were measured at disease 
onset. OR=odds ratio. PaO2=partial pressure of arterial oxygen. FIO2=fraction of inspired oxygen. SOFA=sequential 
organ-failure assessment. *Yes versus no (reference). †In thousands of US$, 2014 (source: World Bank).
Table 4: Mixed-effects logistic regression model of factors associated with all-cause hospital mortality
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did not have access to the source data for the patients 
in the enrolling ICUs, so all patients with ARDS in 
participating centres might not have been enrolled. 
However, enrolment of patients from participating 
ICUs met expectations based on recorded 
2013 admission rates, and data from low-recruiting 
ICUs did not differ from those from high-enrolling 
ICUs (data not shown), suggesting the absence of 
reporting biases. We had a robust quality-control 
programme, in which all centres were asked to verify 
data that seemed inconsistent or erroneous. Although 
we have adjusted our analyses to account for known 
measured confounders, some of our findings might 
still have resulted from unmeasured or residual 
confounding. Finally, our assumptions that patients 
discharged from the hospital before day 28 were alive 
at that timepoint, and that inpatients at day 90 survived 
to discharge are further limitations.
In conclusion, this analysis of data from the LUNG 
SAFE study showed important geo-economic differences 
in severity, clinician recognition, and management of 
ARDS, and in patient outcomes. The finding that higher 
income is associated with better survival in the disorder 
is novel, and shows the effect of geo-economic factors in 
critically ill patients.
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